Maharashtra Halts Cadila Aciloc Sales Over Dangerous Brand Confusion
The Maharashtra Food and Drug Administration (FDA) has hit Cadila Pharmaceuticals Ltd. with an immediate order to stop selling and recall several 'Aciloc' branded drugs, seizing stock worth around Rs 2.45 crore across the state. This urgent action, initiated after inspections on July 9 and 10, comes over serious 'brand confusion' concerns that could lead to dangerous medication errors for patients. The problem lies with nearly identical branding for products containing different Active Pharmaceutical Ingredients (APIs): while Aciloc 150 and Aciloc 300 have Ranitidine, their 'Plus' versions – Aciloc 150 Plus and Aciloc 300 Plus – use Famotidine, a completely different drug.
















